851636-83-4

851636-83-4 structure

Name: Cysmethynil
Chemical Name: 2-[5-(3-methylphenyl)-1-octylindol-3-yl]acetamide
CAS Number: 851636-83-4
Molecular Formula: C₂₅H₃₂N₂O
Molecular Weight: 376.53400
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2017-05-05 14:04:40
Modify Date: 2024-01-03 12:48:07
Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research[1][2][3].

Name	2-[5-(3-methylphenyl)-1-octylindol-3-yl]acetamide
Synonyms	9J20 1H-Indole-3-acetamide, 5-(3-methylphenyl)-1-octyl- 2-[5-(3-Methylphenyl)-1-octyl-1H-indol-3-yl]acetamide Cysmethynil 1H-Indole-3-acetamide,5-(3-methylphenyl)-1-octyl

Description	Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Autophagy >> Autophagy
Target	IC50 = 2.4 μM for Icmt
References	[1]. Winter-Vann AM, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4336-41. [2]. Wang M, et al. A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. J Biol Chem. 2008 Jul 4;283(27):18678-84. [3]. Pan Q, et al. Inhibition of isoprenylcysteine carboxylmethyltransferase sensitizes common chemotherapies in cervical cancer via Ras-dependent pathway. Biomed Pharmacother. 2018 Mar;99:169-175. [4]. Zhu C, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022 Aug 4;21(1):159.